INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says

INmune Bio (NASDAQ:INMB) had its price objective increased by stock analysts at Maxim Group from $22.00 to $30.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 222.58% from the stock’s current price.

INMB has been the subject of a number of other research reports. Alliance Global Partners assumed coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 price target for the company. Scotiabank lifted their target price on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, INmune Bio currently has a consensus rating of “Buy” and a consensus target price of $22.80.

INmune Bio Price Performance

INMB stock traded up $0.17 during trading hours on Thursday, reaching $9.30. The stock had a trading volume of 423,289 shares, compared to its average volume of 513,286. The stock has a market capitalization of $206.18 million, a PE ratio of -4.27 and a beta of 1.87. The stock has a 50-day simple moving average of $6.44 and a 200 day simple moving average of $6.11. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Institutional Trading of INmune Bio

Institutional investors have recently added to or reduced their stakes in the company. Financial Advocates Investment Management lifted its holdings in shares of INmune Bio by 17.4% during the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 2,000 shares in the last quarter. Praetorian PR LLC increased its position in INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after acquiring an additional 295,800 shares during the period. State Street Corp raised its stake in INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after purchasing an additional 58,838 shares in the last quarter. Jane Street Group LLC acquired a new stake in INmune Bio in the 3rd quarter worth about $79,000. Finally, XTX Topco Ltd bought a new stake in INmune Bio in the 3rd quarter valued at about $249,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.